Emergent BioSolutions received a modification worth up to $22.3 million to supply BioThrax® to the U.S. Department of War. The first delivery, valued at approximately $7.4 million, will begin this year, with remaining deliveries expected in 2027.
EBS · Emergent BioSolutions Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Emergent BioSolutions reported that, for the three months ended September 30, 2026, revenue fell 52% to $110.0 million and gross margin fell 87% to $15.0 million, alongside a $191.3 million non-cash NARCAN impairment.
Emergent BioSolutions updated full-year 2026 revenue guidance to $600 million to $645 million and adjusted EBITDA to $110 million to $140 million. Third-quarter revenue was $110 million, and CFO Rich Lindahl retires effective December 31, 2026.
Emergent BioSolutions reported third-quarter 2026 total revenues of $110.0 million, down 52%, with a net loss of $32.7 million. The company also revised its full-year 2026 revenue forecast to $600 - $645 million from $645 - $675 million.
Emergent BioSolutions announced Richard Lindahl will retire as CFO effective December 31, 2026, transitioning to an advisor until March 31, 2027. Frank Vargo, currently VP, Treasurer, will serve as Interim CFO beginning January 1, 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 2, 2026TL;DR. Emergent raised full-year adjusted gross margin guidance, generated $122.4 million of year-to-date operating cash flow, reduced debt and expects restructuring to produce approximately $40 million of annualized savings. However, full-year revenue and adjusted EBITDA guidance ranges were revised lower, Q3 revenue declined 52% year over year, and Q3 adjusted EBITDA was a loss of $4.6 million.
- + Full-year adjusted gross margin guidance was raised to 45%-47% from 42%-44%. new
- + Year-to-date operating cash flow increased to $122.4 million from $92.9 million in the prior-year period. new
- + The Government of Canada awarded NARCAN a standing offer that creates a multiyear pathway. new
- + Debt fell to $514 million of gross debt from $693 million a year earlier following a $75 million bond-principal repurchase. new
- + Restructuring actions are expected to generate approximately $40 million of annualized savings. new
- − Q3 adjusted gross margin fell to 28% from 62%, with profitability affected by revenue timing, product mix and commercial-segment competition. new
- − Q3 naloxone revenue declined 42% because of unfavorable U.S. pricing and volume mix, partly offset by Canadian growth. new
- − Commercial revenue is expected to decline 20%-25% in 2026, with performance tracking toward the lower end of that range. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Research
our published analysis of this company-
Research ThesisEmergent BioSolutions (EBS) Q3 2026 Earnings Preview and Forecast
We forecast Q3 2026 revenue of $128M for Emergent BioSolutions, at the top of its $110–130M guidance, and full-year revenue of $690M, above the $645–675M range. The $75M note repurchase is complete, and two smallpox orders the government has not announced yet decide whether 2026 beats.
-
Research ThesisEmergent BioSolutions: leveraged biodefense name trades like a Narcan story while international MCM mix hits 37%
A $413.3M small-cap MCM franchise that has signed a $140M Canada agreement, a $54M ASPR award, and an ACAM2000 modification while net leverage fell to 1.9x and a $50M buyback was reauthorized — yet the equity is the worst YTD performer in the peer set with 19.9% short interest, leaving the print of the next four quarters to test whether the international MCM pivot can offset the Narcan generics drag.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| average price paid | 8.44 | the three months ended September 30, 2026 filing | — |
| Average price paid per share (1) | $8.44 | three months ended September 30, 2026 filing | — |
| cash | $68.1M | the three months ended September 30, 2026 filing | — |
| Segment adjusted gross margin %(2) non-GAAP | 32% | three months ended September 30, 2026 filing | — |
| Segment adjusted gross margin reportable segments: Commercial Products non-GAAP | $14 | three months ended September 30, 2026 filing | — |
| Severance Payments | $8.2 | the three months ended September 30, 2026 filing | — |
| shares | 0M | the three months ended September 30, 2026 filing | — |
| Total restructuring costs | 9.3M | the three months ended September 30, 2026 filing | — |
| Total stock-based compensation expense | $4.2 | three months ended September 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | 143.9M | Twelve months ended September 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 25% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted gross margin % non-GAAP | 49% | YTD 2026 | — |
| Adjusted net income (loss) non-GAAP | $24.1M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted net income (loss) per diluted share non-GAAP | $0.47 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Capital expenditures | $3.3M | Q3 2026 | — |
|
|
|||
| Cash utilized to repurchase Bonds | $68M | Q3 2026 | — |
| Contract modification | $24M | Q3 2026 | — |
| Countries supplied | 13 | YTD 2026 | — |
| Cumulative Operating Cash Flow | $352M | through Q3 2026 | — |
| Gross Debt | $514M | Q3 2026 | — |
| Intangible asset amortization non-GAAP | 7.8M | Quarter Ended September 30, 2026 | — |
| Inventory step-up provision non-GAAP | 2.4M | Nine Months Ended September 30, 2026 | — |
| Net Debt non-GAAP | 338.6M | As of September 30, 2026 | — |
|
|
|||
| Net debt reduction | $418M | through Q3 2026 | — |
| Net Leverage Ratio non-GAAP | 2.4 | As of September 30, 2026 | — |
| New term loan | 150M | April 2026 | — |
| Operating cash flow | $122M | YTD 2026 | — |
| Sales closed | 19 | Q3 2026 | — |
| Severance and restructuring costs (benefits) non-GAAP | 1.3M | Nine Months Ended September 30, 2026 | — |
| Stock-based compensation expense non-GAAP | 0.7M | Quarter Ended September 30, 2026 | — |
| Unsecured Bond Principal repurchased | $75M | Q3 2026 | — |
| MCM Product gross margin percentage | 64% | the three months ended June 30, 2026 filing | — |
| MCM Product segment adjusted gross margin intangible asset amortization exclusion non-GAAP | $7.8M | the three months ended June 30, 2026 filing | — |
| MCM Products gross margin | $107.4M | the three months ended June 30, 2026 filing | — |
| Shares repurchased | 1,066,958 | three months ended June 30, 2026 filing | — |
|
|
|||
| Adjusted EBITDA (Trailing twelve months) non-GAAP | $241M | Twelve months ended June 30, 2026 | — |
| MCM Products segment adjusted gross margin non-GAAP | $116.1M | Q2 2026 | — |
|
|
|||
| Remaining share repurchase authorization | $46.5M | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EBS
this stock
Emergent BioSolutions Inc.
|
$282.78M | -55.5% | -28.8% | — | 19.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.96B | +36.4% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$51.90B | +7.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.28B | +35.3% | +4.3% | 96.0 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 28
Emergent BioSolutions received a modification worth up to $22.3 million to supply BioThrax® to the U.S. Department of War. The first delivery, valued at approximately $7.4 million, will begin this year, with remaining deliveries expected in 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EBS | -8.9% | -11.3% | -39.7% | -19.2% | -55.5% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -5.0% | -5.7% | -36.2% | -15.9% | -62.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.